Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina

Lancet. 1990 Mar 17;335(8690):615-8. doi: 10.1016/0140-6736(90)90407-v.

Abstract

399 out of 474 inpatients with unstable angina were monitored for 48 h and 97 of these were found to be refractory to conventional antianginal treatments and entered a randomised double-blind study. With the initial protocol heparin infusion or bolus were compared with aspirin; with a modified protocol, heparin infusion, the best of these three treatments, was compared with alteplase. Patients were monitored for 3 days after starting treatment and then observed clinically for 4 more days. On the first days of treatment heparin infusion significantly decreased the frequency of angina (by 84-94%), episodes of silent ischaemia (by 71-77%), and the overall duration of ischaemia (by 81-86%). Heparin bolus and aspirin were not effective. Alteplase caused small (non-significant) reductions on the first day only. Only minor bleeding complications occurred.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Aged
  • Analysis of Variance
  • Angina Pectoris / drug therapy*
  • Angina, Unstable / complications
  • Angina, Unstable / drug therapy*
  • Aspirin / administration & dosage
  • Aspirin / therapeutic use*
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Heparin / administration & dosage
  • Heparin / therapeutic use*
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Myocardial Infarction / complications
  • Myocardial Infarction / prevention & control*
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Thrombolytic Therapy*
  • Tissue Plasminogen Activator / administration & dosage
  • Tissue Plasminogen Activator / adverse effects
  • Tissue Plasminogen Activator / therapeutic use*

Substances

  • Heparin
  • Tissue Plasminogen Activator
  • Aspirin